Nicholas Wealth LLC. Sells 1,144 Shares of Eli Lilly and Company (NYSE:LLY)

Nicholas Wealth LLC. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 72.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 436 shares of the company’s stock after selling 1,144 shares during the period. Nicholas Wealth LLC.’s holdings in Eli Lilly and Company were worth $360,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Cetera Investment Advisers grew its holdings in Eli Lilly and Company by 5.9% in the first quarter. Cetera Investment Advisers now owns 246,287 shares of the company’s stock worth $203,411,000 after purchasing an additional 13,689 shares during the period. Avantax Advisory Services Inc. boosted its position in shares of Eli Lilly and Company by 9.7% during the 1st quarter. Avantax Advisory Services Inc. now owns 56,261 shares of the company’s stock worth $46,466,000 after purchasing an additional 4,982 shares in the last quarter. Tempus Wealth Planning LLC boosted its position in shares of Eli Lilly and Company by 5.1% during the 1st quarter. Tempus Wealth Planning LLC now owns 2,891 shares of the company’s stock worth $2,388,000 after purchasing an additional 141 shares in the last quarter. Gilbert & Cook Inc. grew its stake in shares of Eli Lilly and Company by 2.3% in the 1st quarter. Gilbert & Cook Inc. now owns 1,783 shares of the company’s stock valued at $1,472,000 after buying an additional 40 shares during the period. Finally, Tufton Capital Management increased its position in Eli Lilly and Company by 1.6% in the 1st quarter. Tufton Capital Management now owns 4,867 shares of the company’s stock valued at $4,020,000 after buying an additional 78 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wall Street Zen downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, June 28th. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,012.56.

Eli Lilly and Company Stock Up 0.7%

LLY opened at $804.74 on Friday. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm has a market capitalization of $762.69 billion, a P/E ratio of 65.48, a PEG ratio of 1.16 and a beta of 0.40. The company’s 50-day moving average is $770.86 and its 200 day moving average is $800.14. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. Eli Lilly and Company’s quarterly revenue was up 45.2% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.